Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment



Rating:

Share or cite this content

Citations should be made in the following way:
C. Andrejak (Amiens, France). Novel NTM treatments and approaches, repurposed to bacteriophages. Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment

Member's Comments

No comment yet.

Related content which might interest you: Atypical mycobacteriosis : new drugs, new strategies Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease Year: 2004 Novel approach to species identification of nontuberculous mycobacteria Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Genomics-based identification of targets in pathogenic bacteria for potential therapeutic use Source: Annual Congress 2004 - Novel approaches to the treatment of pneumonia Year: 2004 Proteases as tools for diagnosis and novel therapeutics Source: ERS Research Seminar 2015 Year: 2015 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Towards new antituberculotic targets: biochemical characterisation of mycobacterial RNase E/G Source: Annual Congress 2007 - Novel therapeutic targets and disease markers in pulmonary pathology Year: 2007 CF microbiology, emerging pathogens and more treatment options Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults Year: 2013 Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Pathogenicity of NTM: new developments Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007 Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 670-672 Year: 2016 Advances in the diagnosis of mycobacteria infections and challenges of drug susceptibility testing Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019 From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections Source: International Congress 2017 – Scientific year in review Year: 2017 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021